Biologic Therapies cover a wide range of manufacturing platforms and complexity of manufacture. The resulting action of the biologic can dramatically improve medical conditions for a wide range of ailments (cancer, genetic disorders, viral infections, microbiome Therapies and treatments). These products can be manufactured in a large range of Pharmaceutical facility requirements. The Manufacturing process complexity begins with the research and development scale of the operation and then progresses to the manufacturing scale facility. Once a molecule is identified and has proven potential/efficacy, the process of production, extraction or product molecular modifications are defined for the scale of production. Looking at some of the more prevalent Biologic Therapies and their Compound Annual Growth Rates (CAGR), one can speculate where the future investments and facility demands will be focused. Some of the more prevalent therapeutics are: Monoclonal Antibodies (mAbs), Vaccines, Plasma Fractionation, Advanced Therapy Medicinal Products (ATMP), Microbiome Therapeutics, and Oligonucleotide Therapeutics. The future trends are best focused on standardizing the process steps and thereby streamlining product delivery. A standardized class of unit operations can then be focused on the optimal process and ideally would provide a standardized starting point for development labs in general.